Physician profile
Thomas Haggerty
NPI 1356705727
$3,519.45
in general payments reported to CMS, 2019-2025
37 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.75 · 2020: $14.99 · 2021: $104 · 2022: $160 · 2023: $434 · 2024: $1,216 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.26 | 2021-2025 | |
| Amgen INC. | $339.91 | 2024-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $305.84 | 2024-2025 | Airsupra, Breztri, Lokelma |
| Pfizer INC. | $220.18 | 2023-2025 | |
| Abbott Laboratories | $205.87 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $196.80 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $172.71 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $121.53 | 2021-2022 | |
| Corcept Therapeutics | $121.35 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $115.30 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $114.69 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $103.17 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Lilly USA, LLC | $102.53 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $99.13 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Medtronic, INC. | $95.62 | 2023-2025 | Minimed 780g |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.17 | 2023-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $76.57 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $56.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.03 | 2020-2025 | Capvaxive, Gardasil 9, Lagevrio |
| Bausch Health US, LLC | $51.73 | 2024-2025 | Wellbutrin, Aplenzin |
| Tolmar, INC. | $47.31 | 2025 | Jatenzo |
| Radius Health, INC. | $34.58 | 2025 | Tymlos |
| Mannkind Corporation | $34.08 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $32.66 | 2024 | Nuzyra |
| Ascendis Pharma Endocrinology INC | $32.24 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $31.65 | 2023-2024 | Nexletol |
| Alk-Abello, INC | $30.90 | 2025 | Ragwitek, Grastek, Odactra |
| Alexion Pharmaceuticals, INC. | $30.52 | 2024 | Strensiq |
| Insulet Corporation | $25.38 | 2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $21.15 | 2023 | Livalo |
| Astellas Pharma US INC | $21.00 | 2025 | Veozah |
| Seqirus USA INC | $17.73 | 2025 | Flucelvax, Fluad |
| Kyowa Kirin, INC. | $17.62 | 2025 | |
| Baxter Healthcare | $17.44 | 2023 | Starling System |
| Ibsa Pharma INC. | $16.66 | 2024 | Licart, Tirosint |
| Halozyme INC | $16.59 | 2023 | |
| Leo Pharma INC. | $14.99 | 2025 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.